Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hops (*Humulus lupulus* L.) strobile extract is a botanical medicine derived from the female flowers of the hop plant. It is primarily used for its sedative and sleep-promoting properties, often as a component of phytotherapeutic products such as Ze 91019 (a fixed combination with valerian root extract developed by Max Zeller Söhne AG). The hops component acts as a melatonin receptor agonist, helping to regulate circadian rhythms and reduce sleep latency. It is indicated for the treatment of nonorganic insomnia and nonorganic disorders of the sleep-wake schedule. Clinical evaluations, including Phase III trials, have demonstrated its efficacy both as a mono-extract and in combination therapies, showing good tolerability without the 'hangover' effects or habituation associated with synthetic sedatives.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hops.